热门资讯> 正文
FDA OKs Deciphera's ripretinib for GIST
2020-05-16 03:49
The FDA approves Deciphera Pharmaceuticals' (DCPH+6.7%) ripretinib, branded as Qinlock, for the fourth-line treatment of gastrointestinal stromal tumor (GIST).
The agency's action date was August 13.
Trading has yet to resume.
See all stocks on the move »
Now read:Catabasis Pharmaceuticals (CATB) Investor Presentation - Slideshow »
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
